Postpartum SSRI treatment mitigated the negative associations between PPD and later maternal depression, partner relationship satisfaction, and child externalizing problems and ADHD symptoms up to 5 years after childbirth.
Maternal depression during the third trimester, not prenatal SSRI exposure, was associated with higher levels of internalizing and anxiety behaviors in children from 3 to 12 years of age.
There is evidence that depression itself can increase risk for hypertension and preeclampsia. Future studies will help to clarify the complex interaction between depression, SSRI treatment and pre-eclampsia.
Dr. Lee S. Cohen, Director of the Ammon-Pinizzotto Center for Women's Mental Health at Massachusetts General Hospital, recently shared his insights on the long-term behavioral follow-up of children exposed to mood stabilizers and antidepressants with Ob.Gyn News on August 16,
Consistent with other studies, including a large meta-analysis, this study indicates no increased risk of ADHD in offspring following prenatal exposure to antidepressants.
A New Drug Application for zuranolone awaits FDA approval for the treatment of major depressive disorder (MDD) and postpartum depression (PPD).
Analyzing data from nearly 150,000 children with prenatal antidepressant exposure in two healthcare databases, a recent study finds no association between prenatal exposure to antidepressants and risk for neurodevelopmental disorders.
Some studies have demonstrated associations between in utero exposure to antidepressants and cognitive outcomes.
More study is needed regarding the safety of sedative-hypnotic medications during pregnancy.
While questions and controversies remain, the information on long-term neurodevelopmental outcomes in children prenatally exposed to antidepressants is largely reassuring.
